Intellia Therapeutics, Inc. and ReCode Therapeutics have announced a collaborative effort to develop innovative genomic medicines for cystic fibrosis, a genetic disease that affects various organs,

Bristol Myers Squibb has shared that the U.S. Food and Drug Administration accepted the supplemental New Drug Application for Augtyro™ aimed at treating solid tumors in adults and pediatric patients aged 12 and above

Atara Biotherapeutics, Inc, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases,

DelSiTech Ltd., a company specializing in clinical-stage drug delivery and development, has announced a global license and development agreement with Tolmar International Ltd., a fully-integrated pharmaceutical company.

Krystal Biotech, Inc, a biotechnology company, announced today that the U.S. Food and Drug Administration has granted Fast Track Designation for inhaled KB707. This designation aims to expedite the development

HTuO Biosciences, a biotech company specializing in molecular simulation for drug discovery, has recently joined Johnson & Johnson Innovation - JLABS as a resident virtual company.

Corvus Pharmaceuticals, Inc, a biopharmaceutical company focusing on clinical-stage developments, announced new findings on soquelitinib, its leading ITK inhibitor program

Disc Medicine, Inc, a company focused on developing treatments for serious hematologic diseases, announced that the United States Food and Drug Administration has granted Orphan Drug Designation to DISC-3405 for treating polycythemia vera patients.

Nascent Biotech, Inc. recently announced a research collaboration agreement with Manhattan BioSolutions, Inc. The collaboration aims to investigate antibody-drug conjugates utilizing Nascent’s lead clinical candidate

Calibr-Skaggs Institute for Innovative Medicines, the nonprofit arm of Scripps Research focusing on drug development, has revealed an expansion in its collaboration with AbbVie. This extension aims to further investigate Calibr-Skaggs' switchable CAR-T